Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

The clinical trial is for a new drug for people with moderate to severe eczema, the NHS trust says The first UK patient has been recruited to take part in a clinical trial for a new drug for ...

Researchers say a compound called SYM2081 inhibits inflammation-driving mast cells in mice and human skin samples paving the ...

Opens in a new tab or window Share on X ... nemolizumab is specifically indicated for individuals 12 years and older with eczema that is not sufficiently controlled with topical corticosteroids ...

For some people, keeping up with eczema treatments can be difficult, but resources are available to help find relief from the ...

A daily cream containing a GluK2-activating compound could therefore be a promising way to prevent several inflammatory skin conditions.

The acquisition of Yellow Jersey Therapeutics hands J&J an eczema drug that the company says could have “distinctive benefits” over other therapies. J&J expects its pharmaceutical division to deliver ...

“Red light therapy is an energy-based modality that uses specific wavelengths of red and near-infrared light (typically ...

In particular, she cited ongoing phase 3 trials with the topical pan-JAK inhibitor delgocitinib for chronic hand eczema. The FDA accepted the new drug application for delgocitinib for the ...

Opens in a new tab or window Parents of children with eczema are more likely to be short on sleep and to use medication to try to get more of it, a retrospective National Health Interview Survey ...